SABR Versus Radiofrequency Ablation and Cryoablation for Primary Renal Cell Carcinoma: An Economic Evaluation of the FASTRACK II Trial

Abstract

Purpose: The FASTRACK II trial demonstrated the safety and efficacy of SABR in patients with inoperable renal cell carcinoma (RCC). In this study, we investigated whether SABR was cost-effective compared with the thermal ablation strategies of radiofrequency ablation (RFA) and cryoablation (CA). Methods and Materials: The cost-effectiveness analysis was conducted from an Australian public health care system perspective using data from Australian patients enrolled into the FASTRACK II trial and used estimates from the literature for the comparators. Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cance Core Quality of Life ques..